An in-depth evaluation of current clinical trials demonstrates that only four studies started from 2016 combine ICP therapy (essentially anti-PD-1) with a galectin inhibitor (including anti-Gal-3 or anti-TIM-3) against solid tumors (Table 6), including melanoma, NSCLC, and HNSCC. Here, LGALS3 is linked to melanoma.